A Unique Opportunity for an Intercultural Discussion on CAM and Liver Disease: APASL, Asian Pacific Association for the Study of the Liver, December 2004, New Delhi, India by Marotta, Francesco
The meeting was held under the patronage of the APASL
Executive Committee and the Board of Presidents of the
National Liver Associations in Asia and in conjunction with
the annual conference of the Indian Association for the Study
of Liver (INASL). The congress was designed to have a core
meeting with three parallel sessions running throughout, dedi-
cated research workshops and intensive breakfast sessions.
The breakfast sessions on December 13th were three clini-
cally oriented meetings, one discussing the benefits, limita-
tions and drawbacks of concomitant drug therapy for liver
disease, another examining the non-hepatotropic viruses that
cause hepatitis and their pleiomorphic manifestations, and the
third on the extra-hepatic manifestations of hepatitis B and C.
The most relevant session was undoubtedly ‘Herbal and
Complementary Medicines in Liver Diseases’, chaired by
Professors Wang (China) and Habibullah (India). After a very
clear overview on the topic from Professor Okita, Professor
Marotta (Italy) made a brief state-of-the-art presentation on the
specific issue of phytotherapeutic compounds in chronic liver
disease and, particularly, in hepatitis C virus (HCV)-related
liver disease, highlighting the wealth of good basic scientific
data on several compounds but the lack of solid and well-
designed clinical data for most of them. In particular, the
erratic pharmacokinetics of sylimarine is one of the reasons for
the growing lack of confidence in most clinicians embarking
upon such studies of this compound, while the rare but severe
side effects of TJ-compounds pose a threat to their future wide
application in clinics of Western countries. On the contrary,
although so far limited by its intravenous administration route,
quality-controlled glycyrrhizin acid-based compounds (SNMCs)
are backed up by a considerable amount of in vitro, in vivo and
clinical data.
Given the worthwhile Japanese data (mostly from Professor
Tarao), proving that a hyper-transaminasemic state is a predic-
tor of higher HCC transformation during the year, such com-
pounds may represent a unique therapeutic weapon in patients
with established liver cirrhosis who are not amenable to inter-
feron (IFN) treatments as well as for those who have a poor or
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preliminary suggestions of equipotency of the two arms are
deserving of great attention. Professor Nandini from the Indian
Research Council expressed the Council’s utmost interest in the
scientific and ethical regulation of the matter and called for a
common ground for discussion. He also pointed out the impor-
tance of considering the cost of medication. The discussion
which followed was very exciting ‘Expert clinicians such as
Professor Ferenci, a pioneer in sylimarine research in Austria,
made the disappointing assertion that, given the low costs
of natural compounds, firms could hardly devote any funds
to such worthwhile and badly needed research.’ Other
researchers from India and Western countries emphasized the
great need for such complementary compounds to fill the gaps
in the present chemical treatments such as side effects and
increasing costs. Professor Blum announced an ongoing
SNMC study that he is pursuing at his institution. In summary,
each of these CAM sessions affirmed a definitive role for
validated and quality-controlled phyto-compounds, their
potentially unique benefits including the likelihood of better
compliance by patients and reduced cost. The mandatory task
remains to conduct evidence-based clinical studies that
support such expectations.
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no response to IFN. He also mentioned the even wider poten-
tial application of this compound in other cumbersome clinical
conditions such as non-alcoholic steatohepatitis (NASH),
especially when considering the ongoing search to obtain an
optimal bioavailable oral formulation of SNMC.
Professor Wang described the more than 2000 year experience
of Traditional Chinese Medicine, pointing out the difficult
practical inferences in modern clinical practice. He also pre-
sented interesting recent clinical data on Phyllantus amarus
and oxymatrine in hepatitis B virus (HBV)-related liver disease
and of shisandra and SNMC in HCV-related liver disease. The
session was concluded with a comment by Professor
Habibullah who introduced an extensive survey that he is con-
ducting on CAM practices for liver disease in India with the
aim of regulating such matters while pooling data amenable to
multi-center studies.
Another 2hr workshop was dedicated to this challenging
CAM topic the next day, chaired by an authoritative Indian
opinion leader in hepatology, Professor B. N. Tandom. As the
previous day’s speakers had reported their experience and the
state of the art in their own countries, Professor Acharya also
gave us an update on ongoing research in India. In particular,
he mentioned one double-blind study in which IFN was